LEAN Trial: Liraglutide and NASH resolution The pioneering LEAN (Liraglutide Safety and Efficacy in patients with Non-alcoholic steatohepatitis) trial marked the first rigorous evaluation of GLP-1 agonists for NASH treatment
Drug information Related support groups Ozempic (121 questions, 240 members) Semaglutide (47 questions, 58 members) Diabetes, Type 2 (534 questions, 1,445 members) Facial Wrinkles (18 questions, 36 members) Facial Lipoatrophy (2 questions, 4 members)
Establishing reasonable patient expectations and joint decision-making between patient and clinician are key to achieving patient satisfaction
For many, the risks are vastly outweighed by the benefits: The medication is FDA approved and considered safe to use for weight loss for most people
Oral supplements offer convenient daily administration with various formulation options, though they typically show gradual absorption rates
In the persistent subset, that compensation doesn't happen adequately